What are the new questions regarding HIV treatment? When it comes to hepatitis C, Gilead drugs Harvoni and Sovaldi have validated their value-based care. If faced with the options of spending $577,000 on a liver transplant or $94,500 on a course of Harvoni for hepatitis C, it’s a no brainer which option is more favorable. […]
For employees at Curant Health, caring for patients is a fundamental job role. Advocating on behalf of our patients, verifying and collaborating with insurance payors to ensure accurate flow of information and medication coverage are all daily responsibilities that require a high degree of care and compassion. At Curant Health, we witness our employees dutifully […]
ACG 2015 was a remarkable mixture of clinicians, manufacturers and medical device companies focused on the sharing the new processes, drugs and technology targeted to the gastroenterology space. In addition to IBD-related topics, hepatitis c and new medication therapies were the topic of much discussion. As expected, clinicians provided most of this year’s most valuable conference […]
November 3, 2015 – Curant HCV program director, Amy Hampton, in Managed Healthcare Executive – In August, Bloomberg reported that Gilead, “...is setting ambitious goals to vanquish two major viral scourges: HIV and hepatitis B. The biotech company dominates the HIV market, estimating that about 80% of new patients starting therapy are prescribed a Gilead […]
October 20, 2015 - Curant COO, Marc O'Connor, in MedCity News - Biopharmaceutical manufacturers have been taking it on the chin lately as prices continue to skyrocket. The battery continues as candidates vying for their respective party’s nomination for the 2016 presidential campaign take their positions. As Chris Seper reported via Matthew Herper at Forbes, […]
The newly approved PCSK9 inhibitors are a major advance in cholesterol-lowering drug therapy. Gregory Curfman, MD and Editor in Chief of Harvard Health Publications, has said that this advanced therapy may just rewrite the script for treating patients with chronic high cholesterol. However, this same therapy promises to further raise the stakes in the ongoing match […]
"Biopharmaceutical manufacturers have been taking it on the chin lately as prices continue to skyrocket. The battery continues as candidates vying for their respective party’s nomination for the 2016 presidential campaign take their positions. As Chris Seper reported via Matthew Herper at Forbes, Hillary Clinton and Bernie Sanders both identified the biopharmaceutical industry as their […]
October 2, 2015 - Curant COO, Marc O'Connor and Curant HCV Program Director, Amy Hampton in Managed Healthcare Executive - The days of biopharmaceutical manufacturers and payers operating in isolation are over. Trapped in the firestorm of prior authorizations, high-deductible plans and ultra-high-cost medications are the patients who need all the help they can get […]
All healthcare stakeholders are aware the day is coming when pharma manufacturers will need to go at-risk in order to secure inclusion of their high-cost drugs in plan formularies. This shouldn’t be viewed as simply a unilateral opportunity to force price concessions from manufacturers. Rather, this is an opportunity to place patient outcomes squarely in […]
We’ve talked about who we are: Curant Health is a team of healthcare experts who provide individualized, patient-centered services proven to deliver improved health outcomes. We’ve talked about what we bring to the healthcare table, including the improved outcomes we’ve demonstrated in HIV treatment and diabetes. Now it’s time to talk about ways we enjoy […]
